Lymphocyte transformation by Pim-2 is dependent on nuclear factor-κB activation

被引:81
作者
Hammerman, PS
Fox, CJ
Cinalli, RM
Xu, A
Wagner, JD
Lindsten, T
Thompson, CB
机构
[1] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA
[3] Haverford Coll, Dept Biol, Haverford, PA 19041 USA
关键词
D O I
10.1158/0008-5472.CAN-04-2284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pim-2 is a transcriptionally regulated oncogenic kinase that promotes cell survival in response to a wide variety of proliferative signals. Deregulation of Pim-2 expression has been documented in several human malignancies, including leukemia, lymphoma, and multiple myeloma. Here, we show that the ability of Pim-2 to promote survival of cells is dependent on nuclear factor (NF)-kappaB activation. Pim-2 activates NF-kappaB-dependent gene expression by inducing phosphorylation of the oncogenic serine/threonine kinase Cot, leading to both augmentation. of IkappaB kinase activity and a shift in nuclear NF-kappaB from predominantly p50 homodimers to p50/p65 heterodimers. Blockade of NF-kappaB function eliminates Pim-2-mediated survival in both cell lines and primary cells, and both Cot phosphorylation and expression are required for the prosurvival effects of Pim-2. Although Pim-2 cooperates with Myc to promote growth factor-independent cell proliferation, this feature is abrogated by NF-kappaB blockade. The ability of Pim-2 to serve as an oncogene in vivo depends on sustained NF-kappaB activity. Thus, the transcriptional induction of Pim-2 initiates a novel NF-kappaB activation pathway that regulates cell survival.
引用
收藏
页码:8341 / 8348
页数:8
相关论文
共 44 条
[1]  
Aghajanian C, 2002, CLIN CANCER RES, V8, P2505
[2]   Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc [J].
Allen, JD ;
Verhoeven, E ;
Domen, J ;
vanderValk, M ;
Berns, A .
ONCOGENE, 1997, 15 (10) :1133-1141
[3]   THE HUMAN PROTOONCOGENE PRODUCT P33PIM IS EXPRESSED DURING FETAL HEMATOPOIESIS AND IN DIVERSE LEUKEMIAS [J].
AMSON, R ;
SIGAUX, F ;
PRZEDBORSKI, S ;
FLANDRIN, G ;
GIVOL, D ;
TELERMAN, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8857-8861
[4]   NF-κB1 p105 negatively regulates TPL-2 MEK kinase activity [J].
Beinke, S ;
Deka, J ;
Lang, V ;
Belich, MP ;
Walker, PA ;
Howell, S ;
Smerdon, SJ ;
Gamblin, SJ ;
Ley, SC .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (14) :4739-4752
[5]   TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105 [J].
Belich, MP ;
Salmerón, A ;
Johnston, LH ;
Ley, SC .
NATURE, 1999, 397 (6717) :363-368
[6]  
Castro A, 1999, J IMMUNOL, V162, P1261
[7]  
CHANG CC, 1995, MOL CELL BIOL, V15, P5180
[8]   Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappa B control [J].
Chu, ZL ;
McKinsey, TA ;
Liu, L ;
Gentry, JJ ;
Malim, MH ;
Ballard, DW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) :10057-10062
[9]   A molecular compendium of genes expressed in multiple myeloma [J].
Claudio, JO ;
Masih-Khan, E ;
Tang, HC ;
Gonçalves, J ;
Voralia, M ;
Li, ZH ;
Nadeem, V ;
Cukerman, E ;
Francisco-Pabalan, O ;
Liew, CC ;
Woodgett, JR ;
Stewart, AK .
BLOOD, 2002, 100 (06) :2175-2186
[10]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826